Diagnostics informing treatment of drug resistant infections & cancer.


Friday, 15 September, 2017 -
15:00 to 16:00


Rountree Room 356, Level 3, Biological Sciences Building D26, UNSW Kensington campus


School of Biotechnology and Biomolecular Sciences

Type of event: 


Audience / Guests: 

Public / All

The lecture will outline the evolution of PlexPCR, from PhD project at BABS/UNSW, to the engine that underpins a range of diagnostic tests for personalised medicine. In parallel, it is the story of building SpeeDx, an Australian molecular diagnostics company, from start-up to manufacturer & global distributor of IVD tests tackling global problems including antibiotic resistance for infectious diseases & optimization of cancer therapy. 


Dr Alison Todd has extensive experience within the pharmaceutical industry where she developed several novel molecular analytical technologies which have been used for basic research, preclinical/clinical drug development and in vitro diagnostics. Her specific areas of scientific expertise include nucleic acid chemistry and the biology of cancer and infectious diseases. Prior to co-founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She is an inventor on 16 patents/patent applications and has successfully championed multiple inventions through to product commercialization in various fields. Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class) and later completed a PhD within the Faculty of Medicine. She maintains an active involvement within the academic community and holds an adjunct appointment as Senior Lecturer at the University of New South Wales.